PURPOSE: To better understand the molecular mechanisms of malignant melanoma progression and metastasis, gene expression profiling was done of primary melanomas and melanoma metastases. EXPERIMENTAL DESIGN: Tumor cell-specific gene expression in 19 primary melanomas and 22 melanoma metastases was analyzed using oligonucleotide microarrays after laser-capture microdissection of melanoma cells. Statistical analysis was done by random permutation analysis and support vector machines. Microarray data were further validated by immunohistochemistry and immunoblotting. RESULTS: Overall, 308 genes were identified that showed significant differential expression between primary melanomas and melanoma metastases (false discovery rate<or=0.05). Significantly overrepresented gene ontology categories in the list of 308 genes were cell cycle regulation, mitosis, cell communication, and cell adhesion. Overall, 47 genes showed up-regulation in metastases. These included Cdc6, Cdk1, septin 6, mitosin, kinesin family member 2C, osteopontin, and fibronectin. Down-regulated genes included E-cadherin, fibroblast growth factor binding protein, and desmocollin 1 and desmocollin 3, stratifin/14-3-3sigma, and the chemokine CCL27. Using support vector machine analysis of gene expression data, a performance of >85% correct classifications for primary melanomas and metastases was reached. Further analysis showed that subtypes of primary melanomas displayed characteristic gene expression patterns, as do thin tumors (<or=1.0 mm Breslow thickness) compared with intermediate and thick tumors (>2.0 mm Breslow thickness). CONCLUSIONS: Taken together, this large-scale gene expression study of malignant melanoma identified molecular signatures related to metastasis, melanoma subtypes, and tumor thickness. These findings not only provide deeper insights into the pathogenesis of melanoma progression but may also guide future research on innovative treatments.
PURPOSE: To better understand the molecular mechanisms of malignant melanoma progression and metastasis, gene expression profiling was done of primary melanomas and melanoma metastases. EXPERIMENTAL DESIGN:Tumor cell-specific gene expression in 19 primary melanomas and 22 melanoma metastases was analyzed using oligonucleotide microarrays after laser-capture microdissection of melanoma cells. Statistical analysis was done by random permutation analysis and support vector machines. Microarray data were further validated by immunohistochemistry and immunoblotting. RESULTS: Overall, 308 genes were identified that showed significant differential expression between primary melanomas and melanoma metastases (false discovery rate<or=0.05). Significantly overrepresented gene ontology categories in the list of 308 genes were cell cycle regulation, mitosis, cell communication, and cell adhesion. Overall, 47 genes showed up-regulation in metastases. These included Cdc6, Cdk1, septin 6, mitosin, kinesin family member 2C, osteopontin, and fibronectin. Down-regulated genes included E-cadherin, fibroblast growth factor binding protein, and desmocollin 1 and desmocollin 3, stratifin/14-3-3sigma, and the chemokine CCL27. Using support vector machine analysis of gene expression data, a performance of >85% correct classifications for primary melanomas and metastases was reached. Further analysis showed that subtypes of primary melanomas displayed characteristic gene expression patterns, as do thin tumors (<or=1.0 mm Breslow thickness) compared with intermediate and thick tumors (>2.0 mm Breslow thickness). CONCLUSIONS: Taken together, this large-scale gene expression study of malignant melanoma identified molecular signatures related to metastasis, melanoma subtypes, and tumor thickness. These findings not only provide deeper insights into the pathogenesis of melanoma progression but may also guide future research on innovative treatments.
Authors: Zachary Hothem; Andrew Bayci; Bryan J Thibodeau; Billie E Ketelsen; Laura E Fortier; Alison F Uzieblo; Diane Cosner; Kristin Totoraitis; Richard D Keidan; George D Wilson Journal: Mol Cell Oncol Date: 2016-11-08
Authors: Adam I Riker; Steven A Enkemann; Oystein Fodstad; Suhu Liu; Suping Ren; Christopher Morris; Yaguang Xi; Paul Howell; Brandon Metge; Rajeev S Samant; Lalita A Shevde; Wenbin Li; Steven Eschrich; Adil Daud; Jingfang Ju; Jaime Matta Journal: BMC Med Genomics Date: 2008-04-28 Impact factor: 3.063
Authors: Kian Kani; Carolina Garri; Katrin Tiemann; Paymaneh D Malihi; Vasu Punj; Anthony L Nguyen; Janet Lee; Lindsey D Hughes; Ruth M Alvarez; Damien M Wood; Ah Young Joo; Jonathan E Katz; David B Agus; Parag Mallick Journal: Mol Cancer Ther Date: 2017-05-31 Impact factor: 6.261
Authors: Lindsay G Wich; Heather K Hamilton; Richard L Shapiro; Anna Pavlick; Russell S Berman; David Polsky; Judith D Goldberg; Eva Hernando; Prashiela Manga; Michelle Krogsgaard; Hideko Kamino; Farbod Darvishian; Peng Lee; Seth J Orlow; Harry Ostrer; Nina Bhardwaj; Iman Osman Journal: Am J Transl Res Date: 2009-01-01 Impact factor: 4.060
Authors: Melanie A Warycha; Paul J Christos; Madhu Mazumdar; Farbod Darvishian; Richard L Shapiro; Russell S Berman; Anna C Pavlick; Alfred W Kopf; David Polsky; Iman Osman Journal: Cancer Date: 2008-12-15 Impact factor: 6.860
Authors: Bruce Ng; Jan Zakrzewski; Melanie Warycha; Paul J Christos; Dean F Bajorin; Richard L Shapiro; Russell S Berman; Anna C Pavlick; David Polsky; Madhu Mazumdar; Anthony Montgomery; Leonard Liebes; Peter C Brooks; Iman Osman Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: Rafael A Irizarry; Christine Ladd-Acosta; Andrew P Feinberg; Bo Wen; Zhijin Wu; Carolina Montano; Patrick Onyango; Hengmi Cui; Kevin Gabo; Michael Rongione; Maree Webster; Hong Ji; James Potash; Sarven Sabunciyan Journal: Nat Genet Date: 2009-01-18 Impact factor: 38.330